Cara Therapeutics, Inc. revenue breakdown overview

Cara Therapeutics, Inc. revenue for the last year amounted to 20.97 M USD, the most of which — 20.97 M USD — came from its highest performing source at the moment, Difelikefalin-based Product, the year earlier bringing 41.87 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Cara Therapeutics, Inc. 20.97 M USD, and the year before that — 41.87 M USD.